Author

Xiaolan Ding

Columbia University Irving Medical CenterORCID 0000-0001-9044-784XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

Andrew Kelvin SewelliD· 1 shared Audrey V. ParentiD· 1 shared Austin CheniD· 1 shared Daniel TraumiD· 1 shared Edwin BremeriD· 1 shared Farshid FathiiD· 1 shared Giorgia ZanettiiD· 1 shared Hao Wei LiiD· 1 shared

Activity by Year

2026-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

Andrew Kelvin SewellORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

A universal platform for simultaneous TCRα/β removal enables safer and more potent TCR therapies and autoimmune modeling

Giorgia Zanetti, Mateusz Legut, Austin Chen, Farshid Fathi, Nathan Suek, Nato Teteloshvili, Hao Wei Li, Xiaolan Ding, Daniel Traum, Klaus H. Kaestner, Ryan E. Hoang, Edwin Bremer, Andrew Kelvin Sewell, Audrey V. Parent, Rémi J. Creusot, , Mohsen Khosravi Maharlooei

This paper presents a CRISPR-based platform that removes endogenous TCRα/β chains to enhance transgenic TCR function and safety in T-cell therapies and autoimmune modeling.

bioRxiv · Feb 20, 2026 · PreprintImmunology